DrugTimes001管理团队
DrugTimes001
214
文章
0
粉丝
-
Once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety【IND enabling】
For any questions, please contact DrugTimes BD Team at BD@drugtimes.cn, please include Project ID in the subject. Many thanks!
-
Join Us Live: China Innovative Drug Summit & GenSci R&D Day 2025 – Register Now!
We cordially invite you to join us live on May 17 as we work together to accelerate the globalization of China’s innovative drugs. See you online!
-
A 70-year relay to end the dilemma of no quality treatment for thyroid eye disease patients in China
This is an inspiring story of drug development for patients in great need
-
Disruptive change? How should we really view the new FDA policies?
For more reports, please follow DrugTimes. Many thanks!
-
Trump: The United States will impose tariffs on pharmaceuticals!
For more reports, please follow DrugTimes. Many thanks!
-
The resignation letter of FDA CBER Director Peter Marks, MD, PhD
For more reports, please follow DrugTimes
-
FDA CBER主任Peter Marks博士的辞职信（附：中英文版本）
仅供感兴趣的专业人士朋友们个人谨慎参考。欢迎大家对中文译文进行批评指正！
-
Boston’s Biotech Winter: The Industry’s Growing Pains from Hope to Anxiety—The Dilemma and Future of the Global Biotech Hub
DrugTimes will continue to follow and report on this key topic
-
The Three Fates of Newco and the Birth of LIDNewco
LIDNewCo=License In-Development-NewCo model, is the 2.0 version of NewCo
-
Johnson vs. Johnson!
For more reports, please follow DrugTimes
点击查看更多
